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1229follow-up angiography at 10 months after PCI was
performed in all patients, and percent diameter
stenosis was signiﬁcantly smaller in the group
with calcium fracture compared with the group
without calcium fracture (19  27% vs. 38  38%;
p ¼ 0.030). The frequency of binary restenosis
(14% vs. 41%; p ¼ 0.024) and ischemic-driven
target lesion revascularization (7% vs. 28%; p ¼
0.046) were signiﬁcantly lower in the group with
calcium fracture compared with the group without
calcium fracture.
OCT offers a unique opportunity to observe plaque
modiﬁcation after PCI in the severe calciﬁed lesion.
Coronary calcium fracture by PCI was associated with
adequate stent expansion and favorable late out-
comes. Our ﬁndings support and underline the need
for optimal lesion preparation in the treatment of
heavily calciﬁed lesions.Takashi Kubo, MD, PhD*
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Sympathetic Nerve PET Tracer LMI1195
in the Isolated Perfused Rabbit HeartA radionuclide tracer approach is a unique assay
to monitor the cardiac sympathetic nervous sys-
tem in patients, and the most widely available
tracer is the radiolabeled norepinephrine analogue
[123I]-metaiodobenzylguanidine ([123I]-MIBG). A novel
18F-labeled positron emission tomography (PET)
tracer, [18F]-LMI1195 (N-[3-bromo-4-(3-[18F]ﬂuoro-
propoxy)-benzyl]-guanidine), has been developed to
overcome the limitations of conventional tracers (1).
[18F]-LMI1195 shares similarities with [123I]-MIBG
based on its benzylguanidine structure, but higher
sensitivity and speciﬁcity and more accurate quanti-
ﬁcation are expected via the general advantages of
PET over single-photon emission computed tomogra-
phy technology. The high speciﬁcity of [18F]-LMI1195
for the norepinephrine transporter was conﬁr-
med with a cell-binding assay and in vivo imaging
(1,2). Most recently, a human volunteer study
demonstrated promising results with uniform tracer
uptake in the ventricular wall and acceptable radiation
doses (3).
We aimed to evaluate further tracer kinetics at the
nerve terminal. First-pass tracer extraction fraction
(EF) and washout were measured in isolated rabbit
hearts (New Zealand White) to avoid systemic recir-
culation and metabolism of the tracer.
The EF was determined at different ﬂow values
(n ¼ 19). Additionally, the inﬂuence of desipramine
hydrochloride (40 nM) added into the buffer (n ¼ 5)
and reserpine–pre-treated hearts (n ¼ 5) were tested.
Reserpine pre-treatment was performed with intra-
venous injection of reserpine (2 mg/kg) 3 h before the
study.
A second protocol was designed to measure tracer
washout. Hearts were perfused with [18F]-LMI1195
added to the buffer for 10 min (incubation phase)
followed by 25 min of perfusion without tracer
(washout phase). The tracer washout was examined
by control Krebs-Henseleit bicarbonate buffer (n ¼ 9),
and desipramine was added (desipramine-chase;
n ¼ 5), with washout with electrical ﬁeld stimulation
(5 Hz, 5 V, 1 min  5 times at the washout phase;
n ¼ 7).
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1230There was a ﬂow-dependent decrease in the
EF, with 44.4 5.1%, 28.1 6.5%, and 21.5 5.1% using
ﬂow values of 2, 4, and 8 ml/min/g, respectively.
Desipramine, a speciﬁc neural uptake-1 blocker,
decreased the EF signiﬁcantly from 28.1  6.5%
(control) to 4.3  3.8% (p < 0.001). Reserpine, an irre-
versible vesicular monoamine transporter blocker,
pre-treatment did not change the EF (30.1  3.4%;
p ¼ NS) (Figure 1).
There was tracer washout with 0.73  0.18 %/min
in the ﬁrst 20-min measurement. Desipramine added
only during washout phase did not change the
washout rate (0.94  0.12 %/min). On the otherFIGURE 1 Myocardial Kinetics of Novel [18F]-LMI1195 Sympathetic N
(A) In vivo [18F]-LMI1195 positron emission tomography images of a rab
resonance system. High-contrast left ventricular delineation is seen, wit
extraction time activity curves from [18F]-LMI1195 cardiac uptake and w
decrease of tracer extraction is observed after bolus tracer administratio
reserpine pre-treatment did not change the extraction (bottom). BAT ¼hand, electrical ﬁeld stimulation to enhance the ve-
sicular release of norepinephrine increased the
washout rate signiﬁcantly (1.96  0.48 %/min; p <
0.01).
In summary, we measured the myocardial kinetics
of [18F]-LMI1195 with isolated perfused rabbit hearts.
Speciﬁc uptake at the nerve terminal was conﬁrmed
by desipramine sensitive uptake. Furthermore, we
observed enhanced tracer washout with electrical
stimulation, as well as resistance for desipramine
chase, suggesting that the tracer handling in the
nerve terminals was consistent with norepinephrine
vesicular storage and release.ervous Tracer
bit using a clinical positron emission tomography–cardiac magnetic
h minimal tracer activity in the surrounding tissues. (B) Averaged
ashout studies in several isolated rabbit hearts. Flow-dependent
n (top). Desipramine decreased the tracer extraction, whereas
brown adipose tissue; MIP ¼ maximal intensity projection.
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1231The mechanistic insights of [18F]-LMI1195 uptake
assessed in an isolated heart model might be relevant
in the design of clinical imaging protocols, as well as
the interpretation of imaging results in patients.
However, further complementary in vivo animal ex-
periments are needed to conﬁrm and extended these
ﬁndings for clinical studies.Takahiro Higuchi, MD, PhD*
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1445–51.Novel Use of Cardiac Magnetic Resonance
Imaging for the Diagnosis of Cobalt
CardiomyopathyA 54-year-old male patient with bilateral metal-
on-metal hip prosthesis and recently diagnosed
cobalt toxicity presented with gradually worsening
symptoms of heart failure. Serum cobalt (120 mg/l;
normal<1 mg/l) and chromium (108.8 mg/l; normal<1.4
mg/l) levels were signiﬁcantly elevated. Echocardio-
gram showed biventricular dysfunction (Online
Video 1), and coronary angiogram was normal.
Contrast-enhanced cardiac magnetic resonance (CMR)was performed for further evaluation of the non-
ischemic cardiomyopathy.
CMR showed severe biatrial enlargement with
reduced left ventricular ejection fraction (36%) and
right ventricular ejection fraction (39%) (Online
Video 2). Black-blood T2 images showed diffuse
increased signal intensity (Figures 1A and 1B) and
imaging after late gadolinium enhancement (LGE)
revealed diffuse hyperenhancement of the left
ventricle (Figures 1C and 1D).
Endomyocardial biopsy was performed (Figures 1E
and 1F). Iron, Congo red, and thioﬂavin T stains for
amyloid were negative. The patient underwent
replacement of both hip prostheses, which were found
to be surrounded in brown creamy ﬂuid indicative of
metallic debris. After surgery, cobalt (16.6 mg/l) and
chromium (32 mg/l) levels declined. Repeat CMR was
performed 5 months later and did not show any
improvement in biventricular function, T2 imaging, or
LGE. The patient continued to decline clinically and
needed left ventricular assist device implantation.
The degree of hyperenhancement seen indicated
a systemic etiology for the cardiomyopathy. This
pattern of hyperenhancement is typically seen with
cardiac amyloidosis; however, the blood pool ki-
netics were not consistent with amyloidosis. The
toxic levels of cobalt and chromium and the
absence of an alternative cause make cobalt car-
diomyopathy the most likely diagnosis. The diffuse
enhancement on LGE represented the diffuse
ﬁbrosis as seen on the endomyocardial biopsy in the
patient and also seen in other reported cases (1,2).
To our knowledge, this is the ﬁrst report of using
CMR in a patient with suspected cobalt cardiomyopa-
thy. Because there are no conﬁrmatory tests for
this diagnosis (2), our ﬁndings suggest that CMR
may have a role in establishing the diagnosis of
cobalt cardiomyopathy. Moreover, in most previously
described case reports (2,3), surgical removal of the
metal-on-metal hip prosthesis resulted in clinical
improvement. However, in our patient, despite
a decrease in serum cobalt and chromium con-
centrations post-surgery, there was continued clinical
deterioration. It is possible that the CMR ﬁndings as
seen inourpatientmaybe indicativeofapoorprognosis
in patients with cobalt cardiomyopathy.Huma Y. Samar, MD*
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